TY - JOUR
T1 - Development of an Automated and Sensitive Microfluidic Device for
Capturing and Characterizing Circulating Tumor Cells (CTCs) from
Clinical Blood Samples
AU - Paolillo, Carmela
AU - Capoluongo, Ettore Domenico
AU - Gogoi, Priya
AU - Sepehri, Saedeh
AU - Zhou, Yi
AU - Gorin, Michael A.
AU - Gleason, Kyle
AU - Payne, Austin
AU - Boniface, Brian
AU - Cristofanilli, Massimo
AU - Morgan, Todd M.
AU - Fortina, Paolo
AU - Pienta, Kenneth J.
AU - Handique, Kalyan
AU - Wang, Yixin
PY - 2016
Y1 - 2016
N2 - Current analysis of circulating tumor cells (CTCs) is hindered by sub-optimal sensitivity and specificity of devices or assays as well as lack of capability of characterization of CTCs with clinical biomarkers. Here, we validate a novel technology to enrich and characterize CTCs from blood samples of patients with metastatic breast, prostate and colorectal cancers using a microfluidic chip which is processed by using an automated staining and scanning system from sample preparation to image processing. The Celsee system allowed for the detection of CTCs with apparent high sensitivity and specificity (94% sensitivity and 100% specificity). Moreover, the system facilitated rapid capture of CTCs from blood samples and also allowed for downstream characterization of the captured cells by immunohistochemistry, DNA and mRNA fluorescence in-situ hybridization (FISH). In a subset of patients with prostate cancer we compared the technology with a FDA-approved CTC device, CellSearch and found a higher degree of sensitivity with the Celsee instrument. In conclusion, the integrated Celsee system represents a promising CTC technology for enumeration and molecular characterization.
AB - Current analysis of circulating tumor cells (CTCs) is hindered by sub-optimal sensitivity and specificity of devices or assays as well as lack of capability of characterization of CTCs with clinical biomarkers. Here, we validate a novel technology to enrich and characterize CTCs from blood samples of patients with metastatic breast, prostate and colorectal cancers using a microfluidic chip which is processed by using an automated staining and scanning system from sample preparation to image processing. The Celsee system allowed for the detection of CTCs with apparent high sensitivity and specificity (94% sensitivity and 100% specificity). Moreover, the system facilitated rapid capture of CTCs from blood samples and also allowed for downstream characterization of the captured cells by immunohistochemistry, DNA and mRNA fluorescence in-situ hybridization (FISH). In a subset of patients with prostate cancer we compared the technology with a FDA-approved CTC device, CellSearch and found a higher degree of sensitivity with the Celsee instrument. In conclusion, the integrated Celsee system represents a promising CTC technology for enumeration and molecular characterization.
KW - METASTATIC BREAST-CANCER
KW - RESISTANT PROSTATE-CANCER
KW - METASTATIC BREAST-CANCER
KW - RESISTANT PROSTATE-CANCER
UR - http://hdl.handle.net/10807/95654
U2 - 10.1371/journal.pone.0147400
DO - 10.1371/journal.pone.0147400
M3 - Article
VL - 11
SP - 1
EP - 12
JO - PLoS One
JF - PLoS One
SN - 1932-6203
ER -